As second-line therapy for short-term and non-continuous chronic treatment of mild-to- moderate atopic dermatitis in non-immunocompromised patients 3 months old and older <20210427>.
#仿單變更2021

Pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. Therefore it inhibits T-cell activation by inhibiting the synthesis and release of cytokines from T-cells. Pimecrolimus also prevents the release of inflammatory cytokines and mediators from mast cells.

For the topical route, systemic absorption is minimal in patients with atopic dermatitis.

Hypersensitivity to pimecrolimus or any of the components of the cream.

C [FDA]

Infant risk cannot be ruled out, avoided.

Sensation of burning of skin, at risk for viral infection, headache

Apply a thin layer of pimecrolimus cream only to the affected skin areas, twice a day. Do not use with occlusive dressings.

Refer to adult dosing.